Tyra Biosciences, Inc. (NASDAQ:TYRA) Short Interest Update

Tyra Biosciences, Inc. (NASDAQ:TYRA) was the recipient of a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 3,680,000 shares, an increase of 30.5% from the January 31st total of 2,820,000 shares. Based on an average daily volume of 234,600 shares, the short-interest ratio is presently 15.7 days. Approximately 11.9% of the shares of the company are sold short.

Insider Buying and Selling

In related news, Director Nina S. Kjellson sold 3,993 shares of Tyra Biosciences stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $16.36, for a total value of $65,325.48. Following the transaction, the director now directly owns 3,707,420 shares in the company, valued at $60,653,391.20. This trade represents a 0.11 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders sold a total of 21,998 shares of company stock worth $344,818 in the last 90 days. Company insiders own 15.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of TYRA. Alta Partners Management Company L.P. purchased a new position in Tyra Biosciences during the fourth quarter worth $56,716,000. Boxer Capital Management LLC acquired a new stake in shares of Tyra Biosciences during the fourth quarter valued at $28,185,000. Janus Henderson Group PLC acquired a new position in Tyra Biosciences in the 3rd quarter valued at about $24,994,000. Farallon Capital Management LLC purchased a new position in Tyra Biosciences in the 4th quarter valued at about $13,914,000. Finally, Vestal Point Capital LP acquired a new stake in shares of Tyra Biosciences during the 4th quarter worth about $13,761,000. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Tyra Biosciences in a research note on Tuesday, February 18th. UBS Group began coverage on Tyra Biosciences in a research report on Tuesday, January 7th. They set a “buy” rating and a $28.00 target price on the stock. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $30.50.

Tyra Biosciences Stock Performance

Tyra Biosciences stock opened at $11.10 on Thursday. The firm has a market capitalization of $561.69 million, a price-to-earnings ratio of -6.89 and a beta of 1.05. Tyra Biosciences has a fifty-two week low of $10.65 and a fifty-two week high of $29.60. The stock’s fifty day moving average is $14.10 and its two-hundred day moving average is $17.70.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.